Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CVRx has presented positive two-year data from the European clinical trial evaluating the Rheos hypertension system.
Subscribe to our email newsletter
Of the 45 patients enrolled in this study, 16 patients from four European centers have completed two years of Rheos hypertension (HT) therapy. Blood pressure measurements were taken in the clinic and after two years showed: systolic blood pressure was reduced by an average of 35mmHg and diastolic blood pressure was reduced by an average of 24mmHg.
Similar results were found at three months and one year of Rheos HT therapy. Patients remained on background medical therapy during the trial. During the two-year study period, the average number of antihypertensive medications remained stable.
A drop in systolic blood pressure of at least 20mmHg was achieved in 12 of the 16 patients (75%). The Rheos implants were well tolerated, and there were no unanticipated adverse events related to the system or procedure.
The Rheos HT system is said to be the only implantable medical device designed to control hypertension, or high blood pressure. The device activates the body’s own system for regulating blood pressure.